Syntara
Sydney · Founded 1998
About Syntara
Syntara is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. We are targeting extracellular matrix dysfunction with our world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. Our experienced team of scientists is focusing on correcting extracellular matrix (ECM) dysfunction. The ECM is a crucial component of the cell microenvironment, both under normal as well as fibrotic and inflammatory-driven disease states. By developing effective inhibitors of the key enzymes involved, we can correct dysfunction within the ECM, leading to positive outcomes in a range of diseases with high unmet need, including haematological malignancies such as myelofibrosis and myelodysplastic syndrome, chronic fibrosis (including skin scarring, pulmonary fibrosis, chronic kidney disease, NASH and cardiac fibrosis) and neuroinflammation.
Company Facts
- Founded: 1998
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $1.4M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2009)
- Ticker: asx:PXS
- Website: http://www.syntaratx.com.au
- Phone: 61 2 9454 7200
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Product Research
Social Profiles
Canonical: https://fsome.com/organization/syntara-2910464 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.